Page 67 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology TCM regulates gut microbiota in pediatric MP pneumonia

chemokine CXCL8 acts as a natural mechanism to limit Nat Rev Microbiol. 2017;15(1):55-63.
acute inflammation. Cell Mol Life Sci. 2023;80(1):35.
doi: 10.1038/nrmicro.2016.142
doi: 10.1007/s00018-022-04663-x
66. Yang Q, Hao M, Jiang H. Changes of inflammatory factors
55. Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, and bacterial flora in lung and intestinal tissues by Chinese
Zang X. The third group of the B7-CD28 immune checkpoint herbal medicine intervention in pulmonary diseases based
family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev. on “lung and large intestine compare with each other”.
2017;276(1):26-39. J Pract Chin Med. 2024;38(3):136-138.
doi: 10.1111/imr.12521 doi: 10.13729/j.issn.1671-7813.Z20230203
56. Liu YL, Shang YF, Gui MZ, Li QH. Diagnostic value of 67. Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids:
combined serum CCL5 and sB7-H3 levels for refractory Linking diet, the microbiome and immunity. Nat Rev
mycoplasma pneumonia in children. J Clin Pulmonol. Immunol. 2024;24(8):577-595.
2024;29(4):492-496. doi: 10.1038/s41577-024-01014-8
57. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its 68. Yang D, Lin J, Wang T, Liu H. Progress in the study of disease
receptors: A highly regulated and dynamic system. Cytokine. intervention by Chinese medicines regulating metabolites of
2014;70(1):11-20. intestinal flora. J Bioeng. 2025:1-30.
doi: 10.1016/j.cyto.2014.05.024 doi: 10.13345/j.cjb.240996
58. Zhu Y. Exploring Prescription Drug Use Patterns and 69. Zhao W, Duan C, Liu Y, et al. Modulating effects of Astragalus
Mechanisms of Action of Mycoplasma pneumoniae polysaccharide on immune disorders via gut microbiota
Pneumonia in Children Based on Data Mining and Network and the TLR4/NF-κB pathway in rats with syndrome of
Pharmacology. Master; 2023. Available from: https://link. dampness stagnancy due to spleen deficiency. J Zhejiang
cnki.net [Last accessed 2025 Mar 20]. Univ Sci B. 2023;24(7):650-662.
59. Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, doi: 10.1631/jzus.B2200491
Al-Mssallem MQ. Flavonoids as potential anti-inflammatory
molecules: A review. Molecules. 2022;27(9):2901. 70. Dong K, Gao Y, Qin N, Su L. Effects of Ginseng Ling Bai Zhu
San on antibiotic-induced intestinal flora dysbiosis in mice.
doi: 10.3390/molecules27092901 Chin J Exp Formulas. 2015;21(1):154-157.
60. Yang Y. Exploring the mechanism of action of Er Chen Tang doi: 10.13422/j.cnki.syfjx.2015010154
in the treatment of chronic bronchitis based on network
pharmacology and molecular docking. Med Inform. 71. Mitchell TJ, Dalziel CE. The biology of pneumolysin. Subcell
2024;37(13):7-12. Biochem. 2014;80:145-160.
61. Tang X, Liu J, Dong W., et al. Interventional effects of doi: 10.1007/978-94-017-8881-6_8
quercetin on inflammatory secretion of cardiac fibroblasts 72. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role
in rat suckling mice. Chin J Tradit Chin Med. 2014;39(12): of Streptococcus pneumoniae virulence factors in host
2314-2317. respiratory colonization and disease. Nat Rev Microbiol.
62. Wang Y, Zhang M, Meng J, Guo B, Wang L. Effect of 2008;6(4):288-301.
naringenin on lung tissue repair and high mobility doi: 10.1038/nrmicro1871
group protein B1/nuclear factor-κB signalling pathway
in Mycoplasma pneumoniae-infected mice. Anhui Med. 73. Witzenrath M, Pache F, Lorenz D, et al. The NLRP3
inflammasome is differentially activated by pneumolysin
2024;28(7):1318-1322+1486.
variants and contributes to host defense in pneumococcal
63. Xia J, Ma J, Zhang R, Yu Y. Mechanism of protection against pneumonia. J Immunol. 2011;187(1):434-440.
Mycoplasma pneumoniae pneumoniae in rats by inhibition
of high mobility group protein/Toll-like receptor 4 pathway doi: 10.4049/jimmunol.1003143
by Sangbaekpi extract. J Paediatr Pharmacol. 2024;30(1):1-5. 74. Guo T, Guo Y, Liu Q, et al. The TCM prescription
Ma-Xing-Shi-Gan-Tang inhibits Streptococcus pneumoniae
doi: 10.13407/j.cnki.jpp.1672-108X.2024.01.001
pathogenesis by targeting pneumolysin. J Ethnopharmacol.
64. Bao S, Yan S, Chen T, Chen J, Li J, Hui Y. Research progress 2021;275:114133.
of lung and intestine combination therapy in the treatment of doi: 10.1016/j.jep.2021.114133
pulmonary diseases. Chin J Exp Formulas. 2022;28(8):116-122.
75. Li Y, Yang Q, Hao M, Zhang K. Exploring the mechanism
doi: 10.13422/j.cnki.syfjx.20220708
of inhibition of influenza virus pneumonitis by Ma Xing
65. Budden KF, Gellatly SL, Wood DL, et al. Emerging Shi Gan Tang based on the lung-intestinal axis. Shizhen
pathogenic links between microbiota and the gut-lung axis. Guomian Guomao. 2024;35(9):2135-2139.

Volume 9 Issue 2 (2025) 59 doi: 10.36922/ejmo.8602